Lynparza maintenance for ovarian cancer – pro
The U.S. Food and Drug Administrationgranted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as detected by an FDA-approved test. Lynparza’s efficacy was examined in a study where 137 participants with gBRCAm-associated ovarian cancer received the drug.
The study was designed to measure objective response rate (ORR), or the percentage of participants who experienced partial shrinkage or complete disappearance of the tumor. Results showed 34 percent of participants experienced ORR for an average of 7.9 months.It is approved in the EU for ovarian cancer and recommended by NCCN. The National Comprehensive Cancer Network (NCCN) clinical practice guidelines for ovarian cancer recommend olaparib or niraparib maintenance therapy after partial or complete response to platinum chemotherapy, irrespective of BRCAm testing, which si the stuation here.
NCCN Ovarian Cancer 2020
Ledermann JA, Pujade-Lauraine E. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. Ther Adv Med Oncol. 2019;11:1758835919849753. Published 2019 May 22. doi:10.1177/1758835919849753
Moore K et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. Presented at ESMO October 2018
iv Raja, F. A., Chopra, N. & Ledermann, J. A. Optimal first-line treatment in ovarian cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 23 Suppl 10, x118-127 (2012